Individual immunotherapy is used in the treatment of a wide variety of autoimmune diseases, with a focus on atopic diseases such as neurodermatitis, psoriasis, eczema and other inflammatory diseases.
In most cases, the cause of these diseases is an imbalance in the immune balance. The aim of the treatment with an individual immunotherapy is to restore the balance and thus alleviate or even free the patient of the symptoms of the disease.
The exogenous and endogenous factors that lead to an autoimmune disease are as diverse as the patient's own symptoms. Individual immunotherapy uses the patient-specific immune response to the individual immune processes. A personalised immunotherapeutic agent is produced from the body's own material (patient's own blood, blood plasma or urine), thus reflecting the entire complexity of the personal immune response. The disease-dependent endotype is thus determined.
The individual immunotherapy is an immunomodulatory therapy. The body's own proteins and protein fractions are slightly modified and returned to the body. There they are recognised as foreign and the formation of antibodies against these slightly altered endogenous proteins is stimulated. The previously excessive reaction can be mitigated and the symptoms can be improved or stopped (theory of the idiotype-anti-idiotype immunocomplex).
In addition to the external effects, individual immunotherapy also shows a change in measurable physiological parameters that can be detected during the inflammatory reaction of atopic patients. The frequent imbalance of the TH1-TH2 immune balance can be regulated.
In view of the fact that more and more people are suffering from atopic diseases, individual immunotherapy as a gentle method of treatment offers a real opportunity as well as hope for those affected.
Depending on age, diagnosis and severity of the disease, the optimal form of therapy is selected in consultation between therapist and patient.
The individual immunotherapy based on the patient's own whole blood or blood plasma is an immunomodulatory therapy. The patient-specific immune response to the individual immune processes, which is reflected in the body's own source materials, serves as a basis for the production of individual, personalised immunotherapeutic agents. The immunomodulatory effect of the individual immunotherapeutic agents can thus address the actual cause of the disease. Based on previous experience, the treatment is almost free of side effects due to the use of autologous (the body’s own) substances. It is free of cortisone and synthetic ingredients.
It is mainly used in patients with atopic diseases, as well as in inflammatory diseases of the gastrointestinal tract and respiratory passages.
The main indications are:
The dosage form and dosage of the drugs can be as individual as the composition of the patient's own drug.
Individual immunotherapeutic agents based on blood/blood plasma are offered as drop preparations or as combination preparations in the form of drops and syringes for subcutaneous (under-the-skin) injection. The number and amount of dilutions varies depending on the severity of the disease and the patient's age.
The patient receives the personalised drugs produced especially for him/her in defined dilutions. A gradual increase in the dosage in terms of the number of drops or injection volume gradually adapts the body to the drug, allowing it to develop its immunomodulatory properties in a well-tolerated manner.
All preparations can also be provided as an inhalant. Use in this form usually takes place in addition to the main therapy in the form of syringes and/or drops.
An individual dosage schedule, that is included with each drug, facilitates the use of the drugs.
The type of therapy and its dosage are selected depending on age, diagnosis and severity of the disease.
Immunotherapeutic agents based on the patient's own blood are used especially in moderate to severe forms of autoimmune diseases, whereas immunotherapeutic agents based on the patient's own blood plasma are very well suited for mild to moderate symptoms.
Products based on the patient's own urine are used for mild forms of a disease and especially for the treatment of children. More information can be found under the section about urexent®.
The AHIT® therapy was developed in 1985 by the Ludwigshafen-based physician Dr. med Horst Kief and is a therapeutic approach for the individual-specific treatment of diseases caused by a malfunction of the human immune system. Personalised drugs are produced from the blood and urine of the patient, which are individually adapted to the individual's needs by means of a special antigen selection and are thus modified to complement them.
It is mainly used in patients with atopic or rheumatic diseases.
The main indications are:
To present you the basic information in advance: right here the most important questions and answers...
We frequently receive letters from our patients that we'd like to share with you.